1. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
- Author
-
Girard, Pierre-Marie, Cabié, André, Michelet, Christian, Verdon, Renaud, Katlama, Christine, Mercié, Patrick, Morand-Joubert, Laurence, Pétour, Pascal, Monchecourt, Françoise, Chêne, Geneviève, and Trylesinski, Aldo
- Subjects
- *
ANTIRETROVIRAL agents , *MEDICAL virology , *HIV-positive persons , *VIRAL load , *MEDICAL centers , *CLINICAL trials , *MEDICAL protocols - Abstract
Objectives To assess simplified maintenance regimens containing dual antiretroviral drugs in patients with controlled human immunodeficiency virus type 1 infection. Methods A non-inferiority, randomized, multicentre, open-label trial was performed in 24 AIDS clinical centres in France randomizing 143 patients [treated for ≥6 months, plasma viral load (pVL) Results Success rates for the intention-to-treat analysis were 97.2% (70/72) versus 81.7% (58/71) in the three-drug versus two-drug maintenance regimen groups, respectively [difference, 15.5%; upper limit of one-sided 95% confidence interval (CI), 23.7%], and 100% (70/70) versus 90% (54/60) for the per protocol analysis, respectively (difference, 10%; upper limit of one-sided 95% CI, 16.4%), with a non-inferiority margin set at 14%. Three patients from the two-drug group experienced virological failure with selection of efavirenz-associated mutations. Overall, CD4 counts were significantly increased from baseline (median, +24 cells/mm3; P = 0.007). Four patients discontinued study treatment due to adverse events in the two-drug group and none in the three-drug group. No significant changes in creatinine clearance or phosphataemia were reported. Overall, levels of triglycerides, total and high-density lipoprotein cholesterol were improved; low-density lipoprotein cholesterol was improved only in the three-drug group. Conclusions The non-inferiority of the two-drug versus the three-drug regimen was not demonstrated. Lipid parameters improved after switching from twice-daily highly active antiretroviral therapy (HAART) to once-daily tenofovir-based HAART. [ABSTRACT FROM AUTHOR]
- Published
- 2009